

## Theralase Technologies Inc. Extends Closing of Equity Financing

For Immediate Release

Toronto, Ontario - July 3<sup>rd</sup>, 2007

Theralase Technologies Inc. (TSXV: TLT & OTC BB: TLTF) announces that it will extend the closing date of its equity financing to secure financing for the Company of up to \$5 million CDN. The private placement closing is being extended from June 29th to July 17th to allow committed accredited investors additional time to submit their paperwork. The financing will be offered through a private placement of the Company's securities and commenced on June 4<sup>th</sup>, 2007.

The pricing of the private placement is \$0.50 CDN per unit consisting of one common share and ½ purchase warrant. A full warrant can be exercised at \$0.75 CDN and will expire 12 months after the closing date. Marketing of the Company's securities commenced on June 4<sup>th</sup>, 2007, with the financing closing on or about July 17<sup>th</sup>, 2007. The securities will be offered to accredited investors only in Canada and the United States, in full compliance of National Instrument 45-106. The use of the expected funds is for US market expansion, TLC-2000 biomedical laser commercialization, TLC-2000 biomedical laser FDA clinical study and TLC-3000 Photodynamic Compound and biomedical laser research and development.

Theralase Technologies Inc. designs, develops, manufactures and sells leading edge, proprietary, high powered, super-pulsed therapeutic laser equipment employed in a wide range of biostimulative medical therapy applications. The Theralase technology platform targets several diverse healthcare sectors -- firstly, for non-invasive pain management, control and therapy, including a wide range of neural-musculo-skeletal conditions, arthritic and rheumatologic disorders -- secondly, to bio-stimulate and accelerate wound care and healing, including: bone fracture regeneration and osteoarthritic conditions -- and thirdly, combining proprietary metallic complexes with photo-dynamic lasers to attack specifically-targeted cancerous growths. For a complete profile of Theralase Technologies Inc. and its products visit [www.theralase.com](http://www.theralase.com).

For further Information, please contact:

Roger Dumoulin-White  
President & CEO  
Phone: (905) 947-8455  
e-mail: [rwhite@theralase.com](mailto:rwhite@theralase.com)

*This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.*

*The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.*